Use of emollients in dry-skin conditions: Consensus statement

Clinical and Experimental Dermatology

Volumn 38, Issue 3, 2013, Pages 231-238

  Moncrieff, G ^a   Cork, M ^b,c,d   Lawton, S ^e   Kokiet, S ^f   Daly, C ^g   Clark, C ^h  

^a Health Centre   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f Bedford House Medical Centre   (United Kingdom)

^g Mid Norfolk Clinical Commissioning Group   (United Kingdom)

^h Christine Clark Ltd Lancashire   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EMOLLIENT AGENT;

ATOPIC DERMATITIS; CLINICAL PRACTICE; COMMUNITY CARE; DRUG EFFICACY; DRUG USE; DRY SKIN; ECZEMA; ENVIRONMENTAL FACTOR; HUMAN; ICHTHYOSIS; IRRITANT DERMATITIS; PATIENT EDUCATION; PRIORITY JOURNAL; PSORIASIS; REVIEW; STRATUM CORNEUM;

CONSENSUS; EMOLLIENTS; GREAT BRITAIN; HUMANS; SKIN DISEASES;

EID: 84875326629     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12104     Document Type: Review

References (48)

1. Proksch E, Lachapelle JM,. The management of dry skin with topical emollients-recent perspectives. J Dtsch Dermatol Ges 2005; 3: 768-74.
2. Baron SE, Cohen SN, Archer CB,. Guidance on the diagnosis and clinical management of atopic eczema. Clin Exp Dermatol 2012; 37 (Suppl. 1): 7-12.
3. Rawlings A, Matts PJ, Anderson CD, Roberts MS,. Skin biology, xerosis, barrier repair and measurement. Drug Disc Today Dis Mech 2008; 5: e127-36.
4. Cork MJ, Danby SG, Vasilopoulos Y, et al,. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129: 1892-908.
5. Rippke F, Schreiner V, Doering T, Maibach HI,. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus aureus. Am J Clin Dermatol 2004; 5: 217-23.
6. Bohme M, Soderhall C, Kull I, et al,. Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. J Allergy Clin Immunol 2012; 129: 1153-5.
7. Flohr C, England K, Radulovic S, et al,. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol 2010; 163: 1333-6.
8. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
9. Harding C, Bartolone J, Rawlings A,. Effects of natural moisturizing factor and lactic acid isomers on skin function. In: Dry Skin and Moisturizers: Chemistry and Function (, Loden M, Maibach H, ed). Boca Raton: CRC Press, 2000; 229-41.
10. Ananthapadmanabhan KP, Moore DJ, Subramanyan K, et al,. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther 2004; 17 (Suppl. 1): 16-25.
11. Seyfarth F, Schliemann S, Antonov D, Elsner P,. Dry skin, barrier function, and irritant contact dermatitis in the elderly. Clin Dermatol 2011; 29: 31-6.
12. Stamatas GN, Nikolovski J, Mack MC, Kollias N,. Infant skin physiology and development during the first years of life: a review of recent findings based on in vivo studies. Int J Cosmet Sci 2011; 33: 17-24.
13. Bissonnette R, Maari C, Provost N, et al,. A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. J Cosmet Dermatol 2010; 9: 16-21.
14. Wiren K, Nohlgard C, Nyberg F, et al,. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2009; 23: 1267-72.
15. Chamlin SL, Kao J, Frieden IJ, et al,. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47: 198-208.
16. Msika P, De Belilovsky C, Piccardi N, et al,. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol 2008; 25: 606-12.
17. Cork MJ, Danby S,. Skin barrier breakdown: a renaissance in emollient therapy. Br J Nurs 2009; 18: 872-7.
18. Lawton S,. Practical issues for emollient therapy in dry and itchy skin. Br J Nurs 2009; 18: 978-84.
19. Cork MJ, Timmins J, Holden C, et al,. An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharmaceut J 2003; 271: 746-7.
20. Danby S, Al Enezi T, Sultan A, et al,. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol 2011; 165: 329-34.
21. Tupker RA, Willis C, Berardesca E, et al,. Guidelines on sodium lauryl sulfate (SLS) exposure tests. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1997; 37: 53-69.
22. British Pharmacopoeia Commission. British Pharmacopoeia. London: Pharmaceutical Press, 1958.
23. Primary Care Dermatology Society and British Association of Dermatologists. Guidelines on the Management of Atopic Eczema, Vol. 39. Berkhamsted: Medendium Group Publishing, 2009; 399-402.
24. Lewis-Jones S, Cork MJ, Clark C, et al,. Atopic Eczema in Children-Guideline Consultation: A Systematic Review of the Treatments for Atopic Eczema and Guideline for its Management. London: National Institute for Clinical Excellence (NICE), 2007.
25. Cork MJ, Britton J, Butler L, et al,. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003; 149: 582-9.
26. Schofield J, Grindlay DJ, Williams HC,. Skin Conditions in the UK: A Health Care Needs Assessment. Nottingham: Centre of Evidence-Based Dermatology, University of Nottingham, 1 2009; 1-158. http://www.nottingham.ac.uk/scs/ documents/documentsdivisions/documentsdermatology/hcnaskinconditionsuk2009.pdf.
27. British Association of Dermatologists. Quality Standards for Dermatology. Providing the Right Care for People with Skin Conditions. London: BAD, 2011. Available at: http://www.bad.org.uk/Portals/-Bad/Quality%20Standards/ Dermatology%20Standards%20FINAL%20-%20July%202011.pdf.
28. Ward S,. Eczema and dry skin in older people: identification and management. Br J Community Nurs 2005; 10: 453-6.
29. Cohen SN, Baron SE, Archer CB,. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol 2012; 37 (Suppl. 1): 13-18.
30. Dyble T, Ashton J,. Use of emollients in the treatment of dry skin conditions. Br J Community Nurs 2011; 16: 214-20.
31. Loden M,. Urea-containing moisturizers influence barrier properties of normal skin. Arch Dermatol Res 1996; 288: 103-7.
32. Held E, Sveinsdottir S, Agner T,. Effect of long-term use of moisturizer on skin hydration, barrier function and susceptibility to irritants. Acta Derm Venereol 1999; 79: 49-51.
33. Schrader A, Siefken W, Kueper T, et al,. Effects of glyceryl glucoside on AQP3 expression, barrier function and hydration of human skin. Skin Pharmacol Physiol 2012; 25: 192-9.
34. Buraczewska I, Berne B, Lindberg M, et al,. Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol 2007; 156: 492-8.
35. Spergel JM, Paller AS,. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: S118-27.
36. Cox H, Lloyd K, Williams H, et al,. Emollients, education and quality of life: the RCPCH care pathway for children with eczema. Arch Dis Childhood 2011; 96 (Suppl. 2): i19-24.
37. Wehner J, Neuber K,. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol 2001; 145: 302-5.
38. Cork MJ,. Complete emollient therapy. In: Association of Fundholding Practices Official Yearbook. Dunstable: BPC Waterlow, 1998; 159-68.
39. Grimalt R, Mengeaud V, Cambazard F,. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214: 61-7.
40. Cork MJ, Timmins J, Carr J, et al,. Optimising treatment of atopic dermatitis. The emollient to topical steroid prescribing ratio. Presented at: Derm Update, Montreal, QC, Canada, 2003.
41. Simpson EL, Berry TM, Brown PA, Hanifin JM,. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol 2010; 63: 587-93.
42. Gilani SJ, Gonzalez M, Hussain I, et al,. Staphylococcus aureus re-colonization in atopic dermatitis: beyond the skin. Clin Exp Dermatol 2005; 30: 10-13.
43. Seite S, Khemis A, Rougier A, Ortonne JP,. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. Exp Dermatol 2009; 18: 1076-8.
44. Szczepanowska J, Reich A, Szepietowski JC,. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614-8.
45. Staab D, Diepgen TL, Fartasch M, et al,. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-8.
46. Cassano N, Mantegazza R, Battaglini S, et al,. Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open-label study. G Ital Dermatol Venereol 2010; 145: 789-92.
47. Loden M, Andersson AC,. Effect of topically applied lipids on surfactant-irritated skin. Br J Dermatol 1996; 134: 215-20.
48. Anekwe L,. Focus on: The rise in GP referrals. Pulse London: Briefing Media, 2008.